GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Entry into a Material Definitive Agreement
Item 2.03.Entry into a Material Definitive Agreement.

On November 29, 2018, GenMark Diagnostics, Inc. (the “Company”) entered into a seventh amendment (the “Amendment”) to its Loan and Security Agreement (the “Agreement”) with Solar Senior Capital Ltd., as agent, and the financial institutions that are or become parties to the Agreement as lenders (the “Lenders”). to the Amendment, the Company borrowed from the Lenders an additional approximately $7.1 million under the Agreement in the form of a new term loan (“Term Loan E”). Term Loan E is subject to the same interest-only period, final maturity date, interest rate calculation, and other terms and conditions as the other term loans made available to the Company under the Agreement.

The foregoing description of the terms of the Amendment is qualified in its entirety by reference to the text of such document, a copy of which will be filed in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), with portions omitted and filed separately with the SEC to a request for confidential treatment.

Item 2.03.Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.